Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Metadata listed "Altimmune, Inc." but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. Key product candidates include Valortim (anthrax treatment) and Protexia (nerve agent poisoning treatment). The company operates primarily on government contracts and grants.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenue | $5.84 million | $2.97 million |
| Net Loss | $(5.02) million | $(2.93) million |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(7.50) |
| Cash and Cash Equivalents (End of Period) | $19.24 million | $11.91 million |
| Total Debt (Current + Long Term) | $20.00 million | Filing text does not provide a clear comparable total for Q1 2007 |
| Net Cash Used in Operating Activities | $(5.27) million | $(1.98) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 97% year-over-year, driven primarily by a $2.7 million increase in contract revenue from the U.S. Department of Defense for Protexia development.
- Expense Increase: Operating expenses rose to $10.75 million from $5.72 million. Research and Development (R&D) expenses increased $2.8 million due to process development and manufacturing activities. General and Administrative (G&A) expenses increased $2.2 million due to higher employee costs, stock compensation, and legal/consulting fees.
- Liquidity Impact: Cash and cash equivalents decreased by $21.3 million during the quarter. This decline was primarily due to funding operations, a $10 million deposit for a letter of credit related to the Avecia acquisition, and restricted cash obligations.
- Debt Structure: The company holds $12.3 million in convertible notes and a $10 million credit facility. A loan modification agreement was entered into in March 2008 requiring the company to maintain restricted cash equal to 1.25x its obligations to lenders.
Outlook, Risks, and Unusual Items
- Recent Acquisition: On April 2, 2008 (subsequent to the reporting period), the company completed the acquisition of Avecia Biologics' vaccines business. The deal involved an initial $10 million cash payment and a $7 million deferred payment secured by a letter of credit.
- Future Milestone Payments: The Avecia acquisition includes potential milestone payments totaling up to $23 million plus royalties, contingent on securing specific government contracts for plague and anthrax vaccines.
- Liquidity Constraints: The Loan Modification Agreement restricts available cash by requiring a segregated account holding 1.25 times the debt obligation. Management notes that continuation as a going concern depends on successful R&D and obtaining adequate financing.
- Government Dependence: The company relies heavily on U.S. government contracts (DoD, NIAID, BARDA). Revenue recognition is tied to cost-plus-fee contracts and reimbursable grants.
- Legal Contingency: The company is involved in litigation against SIGA Technologies regarding a terminated merger agreement and potential licensing rights for SIGA-246.
Investor Verification Checklist
- Acquisition Integration: Verify the financial impact and integration progress of the Avecia Biologics acquisition completed in April 2008.
- Cash Burn Rate: Monitor the rate of cash consumption given the restricted cash requirements and the $7 million deferred payment obligation.
- Government Contract Milestones: Track progress on DoD and BARDA contracts for Protexia and Valortim, as these are the primary revenue drivers.
- Debt Covenants: Confirm compliance with the Loan Modification Agreement covenants, specifically the restricted cash maintenance ratio.
- Regulatory Status: Verify the status of FDA Fast Track designation for Valortim and the timeline for the Investigational New Drug (IND) application for Protexia.